Abstract
The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Current Molecular Medicine
Title:Role of Mammalian Target of Rapamycin in Atherosclerosis
Volume: 18 Issue: 4
Author(s): Z. Cai*, Y. He and Y. Chen
Affiliation:
- Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences, 400013, Chongqing,China
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Abstract: The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Export Options
About this article
Cite this article as:
Cai Z. *, He Y. and Chen Y. , Role of Mammalian Target of Rapamycin in Atherosclerosis, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163917
DOI https://dx.doi.org/10.2174/1566524018666180926163917 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Common Variants in Toll-Like Receptor 4 Confer Susceptibility to Alzheimer’s Disease in a Han Chinese Population
Current Alzheimer Research Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry Synergistic Antitumor Effect of 5-Fluorouracil Combined with Constituents from <i>Pleurospermum lindleyanum</i> in Hepatocellular Carcinoma SMMC-7721 Cells
Anti-Cancer Agents in Medicinal Chemistry Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Linezolid Induced Skin Reactions in a Multi Drug Resistant Infective Endocarditis Patient: A Rare Case
Current Drug Safety Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Fetal and Early-Postnatal Developmental Patterns of Obese-Genotype Piglets Exposed to Prenatal Programming by Maternal Over- and Undernutrition
Endocrine, Metabolic & Immune Disorders - Drug Targets Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis
Current Vascular Pharmacology Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued)